TEE Surveillance After Watchman Placement

Standard TEE Surveillance Protocol

A transesophageal echocardiogram (TEE) should be performed at 45 days and 1 year after Watchman left atrial appendage occlusion device placement to evaluate for device-related thrombus and peridevice leak before discontinuing anticoagulation, as recommended by the American College of Cardiology 1

Non-paroxysmal atrial fibrillation is associated with an increased risk of device-related thrombus (OR 1.90–2.24) 1
Renal insufficiency is associated with an increased risk of device-related thrombus (OR 4.02) 1
History of TIA or stroke is associated with an increased risk of device-related thrombus (OR 2.31) 1
Deep device implantation (>10 mm from pulmonary vein limbus) is associated with an increased risk of device-related thrombus (OR 2.41) 1

Clinical Implications

The detection of high-grade hypoattenuated thickening (a form of device-related thrombus) is significantly associated with increased stroke risk (HR 4.6) 1
Any peridevice leak detected by TEE, regardless of size, is associated with increased risk of thromboembolism 1

Anticoagulation Duration After Watchman Device Implantation

Standard Anticoagulation Protocol

The American Heart Association recommends that patients should be treated with warfarin plus aspirin for at least 45 days, followed by dual antiplatelet therapy (aspirin plus clopidogrel) until 6 months post-procedure, and then aspirin alone indefinitely, after Watchman left atrial appendage occlusion device implantation 2, 3
The standard anticoagulation regimen following Watchman implantation consists of warfarin (target INR 2.0-3.0) plus aspirin for at least 45 days post-implantation, aspirin plus clopidogrel from 45 days to 6 months post-implantation, and aspirin alone indefinitely after 6 months 2, 3

Clinical Implications

The American College of Cardiology states that the Watchman device is non-inferior to warfarin for preventing stroke, systemic embolism, and cardiovascular death in patients with non-valvular atrial fibrillation 2, 3
The risk of hemorrhagic stroke is significantly lower with the Watchman device compared to long-term warfarin (RR 0.09; 95% CI 0-0.45) 2

Anticoagulation After Watchman Device Implantation

Introduction to Anticoagulation Regimens

The original PROTECT-AF and PREVAIL trial protocols established the device's non-inferiority to warfarin, with a regimen based on a three-phase approach following Watchman implantation 4

Guideline Recommendations for Anticoagulation

The 2024 ESC Guidelines state that percutaneous LAA occlusion may be considered (Class IIb) in patients with AF and contraindications for long-term anticoagulant treatment 5
The 2018 CHEST Guidelines suggest LAA occlusion only in patients with absolute contraindications to oral anticoagulation (Weak recommendation, low quality evidence) 6

Alternative Anticoagulation Regimens

The 2024 ESC Guidelines note that with DOACs demonstrating similar bleeding rates to aspirin, the role of Watchman in current practice is unclear, as the device trials compared against warfarin, not modern DOACs 5

TEE Assessment for Watchman Device Patients

Technical Considerations

TEE provides superior visualization compared to transthoracic echocardiography for posterior cardiac structures and device assessment, with higher spatial resolution essential for detecting small thrombi and leaks, as stated by the American College of Radiology 7
Ensure adequate sedation for TEE, as hemodynamic changes from sedation may affect valvular flow assessment, though this is less critical for device evaluation than for valvular assessment, according to the American College of Radiology 7

Post-Watchman Device Anticoagulation Management

Standard Protocol Based on Clinical Trial Evidence

The American Heart Association recommends warfarin (target INR 2.0-3.0) plus aspirin for at least 45 days, followed by dual antiplatelet therapy (aspirin plus clopidogrel) from 45 days to 6 months, then aspirin alone indefinitely, for patients with atrial fibrillation who have undergone Watchman device implantation 8, 9
The initial 45-day period requires close anticoagulation monitoring due to high risk of bleeding, with a recommended transesophageal echocardiogram (TEE) at 45 days to evaluate device-related thrombus and peridevice leak 8
Discontinuation of warfarin at 45 days and initiation of dual antiplatelet therapy reduces the risk of intracranial and extracranial hemorrhage 8
Aspirin alone indefinitely is recommended after 6 months, with another TEE recommended at 1 year post-procedure for continued surveillance 8, 9

Evidence Supporting This Regimen

The PROTECT-AF trial demonstrated that LAA closure with the Watchman device was noninferior to warfarin for preventing stroke, systemic embolism, and cardiovascular death, with a relative risk of 0.62 (95% CI 0.35-1.25) 8, 9
Hemorrhagic stroke was significantly lower with the Watchman device compared to long-term warfarin, with a relative risk of 0.09 (95% CI 0-0.45) 8

Alternative Regimens for High Bleeding Risk Patients

The 2019 AHA/ACC/HRS guidelines state that percutaneous LAA occlusion may be considered (Class IIb, Level B-NR) in patients with AF at increased risk of stroke who have contraindications to long-term anticoagulation 10

Important Clinical Caveats

The FDA approval specifies that patients must be deemed suitable for at least short-term warfarin and can tolerate at least 45 days of postprocedural anticoagulation 10, 11
Close monitoring is required during the initial 3-month period after starting warfarin, particularly in elderly patients, to minimize bleeding risk 8, 9

LAA Device Closure and Anticoagulation Recommendations

Indications and Contraindications

The European Society of Cardiology recommends LAA closure for patients with atrial fibrillation at increased stroke risk who have contraindications to long-term oral anticoagulation, as a Class IIb recommendation 12, 13

Standard Post-Procedural Anticoagulation Protocol

The established regimen for post-procedural anticoagulation is oral anticoagulation (warfarin INR 2.0-3.0 or DOAC preferred) plus aspirin for 45 days, based on the PROTECT AF trial which demonstrated non-inferiority to warfarin for preventing stroke, systemic embolism, and cardiovascular death 13

Periprocedural Management

The European Society of Cardiology and Nature Reviews Cardiology suggest that adequate intraprocedural anticoagulation with intravenous heparin is essential, and either DAPT or oral anticoagulation at hospital discharge are protective against device-related thrombus formation 14
The American Heart Association and Nature Reviews Cardiology indicate that protamine use remains controversial, with less major bleeding but higher rates of vascular complications and pericardial tamponade, with no net benefit in major adverse events 14

Echo Parameters for Watchman Device Assessment on TEE

Device Position and Stability

The European Society of Cardiology recommends assessing device position, stability, peridevice leak, device-related thrombus, and potential complications including pericardial effusion and pulmonary vein obstruction when evaluating a Watchman device on TEE 15, 16

Peridevice Leak Assessment

The European Heart Society guidelines suggest that any peridevice leak, regardless of size, is associated with increased risk of thromboembolism and must be carefully characterized, with leak location identified and documented 15, 16
Multiple views, including mid-esophageal views at 0°, 45°, 90°, and 135°, are required to assess for peridevice leak and avoid missing leaks that may only be visible in certain planes 15, 16

The European Society of Cardiology recommends assessing for distinct echodensity, mobility, location, persistence, and differentiation from normal healing when evaluating for device-related thrombus 15, 16
A distinct mass separate from the device fabric, independent motion of the mass relative to device movement, and presence on multiple views and throughout the cardiac cycle are all criteria for device-related thrombus 15, 16

Complete LAA Occlusion

The European Heart Society guidelines recommend confirming complete occlusion of the LAA orifice without flow inside the appendage using color Doppler with optimized settings and assessing throughout multiple cardiac cycles 15, 16, 17

Complications Screening

The European Society of Cardiology recommends systematically screening for procedural complications, including pericardial effusion, left upper pulmonary vein obstruction, mitral valve impingement, and air embolism, using TEE 15, 16, 17, 18
Pericardial effusion, even small effusions, warrant close monitoring as they may indicate perforation 17, 18

Technical Considerations for Optimal Assessment

The American Society of Echocardiography recommends using multiplane TEE with systematic sweeps through 0°, 45°, 90°, and 135° views to fully visualize all aspects of the device and surrounding structures 15, 16
3D TEE provides superior assessment of device morphology, position, and relationship to surrounding structures with en face views from the left atrial perspective 15, 19

Aspirin Regimen After Watchman Device Implantation

Antithrombotic Therapy

The American College of Cardiology recommends an aspirin dose of 81-162 mg daily for patients after Watchman device implantation, as lower doses minimize bleeding risk while maintaining efficacy 20

Special Considerations

No other facts were found with associated citations.

Anticoagulation After Watchman Procedure

Guideline Recommendations

The American Heart Association recommends the Watchman device as a Class 2b recommendation (may be reasonable) for patients with contraindications for lifelong anticoagulation but who can tolerate at least 45 days of post-procedural anticoagulation 21, 22, 23

Device-related thrombus formation occurs in up to 7.2% per year and is associated with ischemic stroke risk during follow-up, with certain patient characteristics such as non-paroxysmal atrial fibrillation (OR 1.90-2.24), renal insufficiency (OR 4.02), and history of TIA or stroke (OR 2.31) increasing the risk of device-related thrombus 21, 22, 23

Post‑WATCHMAN Antithrombotic Strategies – Evidence‑Based Recommendations

DOAC‑Based Alternatives (European practice)

European practice increasingly favors direct oral anticoagulants (DOACs) over warfarin for the first 45 days after WATCHMAN implantation; limited observational data suggest DOACs may be non‑inferior to warfarin for preventing thrombo‑embolic events. Strength of evidence: low‑quality observational. 24

Mandatory Imaging Surveillance (European Society of Cardiology)

The 45‑day transesophageal echocardiogram (TEE) must evaluate device position and stability, per‑device leak, device‑related thrombus, pericardial effusion, pulmonary‑vein obstruction, and mitral‑valve impingement. Strength of evidence: expert consensus (ESC guideline). 24

Anticoagulation Paradox and Regulatory Requirement (FDA/ Circulation)

The standard post‑procedural regimen (warfarin + aspirin → DAPT → aspirin) exposes patients to bleeding risks comparable to DOAC therapy, creating a paradox for patients selected for the device because of bleeding contraindications. Strength of evidence: expert commentary. 24
FDA approval requires patients to be able to tolerate at least 45 days of oral anticoagulation after WATCHMAN implantation. Strength of evidence: regulatory requirement. 25

Real‑World Practice vs. Trial Protocols (European Society of Cardiology)

In routine practice, most centers shorten dual‑antiplatelet therapy to 3 months or adopt alternative regimens, diverging markedly from the trial‑derived three‑phase protocol. Strength of evidence: real‑world observational data. 24
The 2024 ESC Guidelines highlight uncertainty about the device’s role because contemporary DOACs now show bleeding rates similar to aspirin, whereas pivotal trials compared the device only with warfarin. Strength of evidence: guideline uncertainty. 24

Evidence Gaps (European Society of Cardiology)

No randomized controlled trials have compared WATCHMAN implantation directly with DOAC therapy, leaving a major evidence gap. Strength of evidence: absence of RCT data. 24
All efficacy data to date compare the device with warfarin, not with modern DOACs that have superior safety profiles. Strength of evidence: expert consensus. 24